国家药监局12月31日最新药品通知件送达信息显示：九源基因的司美格鲁肽注射液在列，意味着该产品暂时未获批准。

　　今年4月2日，九源基因递交了司美格鲁肽注射液的上市申请并获受理，这也是国内第一家申报上市的司美格鲁肽生物类似药。

　　然而，备受期待的生物制药公司九源基因此前遭遇了上市即破发的尴尬局面。11月28日，发售价为每股12.42港元九源基因（02566.HK）登陆港交所，上市首日开盘价为7.5港元/股，低开39.61%，当日收跌38.41%。截至12月31日，九源基因收跌1.79%，报6.60港元/股，总市值为16.20亿港元，股价依然破发。

（文章来源：深圳商报·读创）

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.